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c on c i s e c ommun i c a t i o n
Development and Application of an
Antibiotic Spectrum Index for Benchmarking
Antibiotic Selection Patterns Across Hospitals
Jeffrey S. Gerber, MD, PhD;1,2 Adam L. Hersh, MD, PhD;3
Matthew P. Kronman, MD, MSCE;4 Jason G. Newland, MD;5
Rachael K. Ross, MPH;1 Talene A. Metjian, PharmD6
Standard metrics for antimicrobial use consider volume but not
spectrum of antimicrobial prescribing. We developed an antibiotic
spectrum index (ASI) to classify commonly used antibiotics based on
activity against important pathogens. The application of this index
to hospital antibiotic use reveals how this tool enhances current
antimicrobial stewardship metrics.
Infect Control Hosp Epidemiol 2017;38:993–997
Antimicrobial stewardship programs (ASPs) aim to optimize
antibiotic prescribing to improve patient outcomes and reduce
unnecessary antimicrobial use.1 Measuring antimicrobial use
is central to evaluating an ASP’s effectiveness and identifying
targets for intervention.2
Antimicrobial use in hospitalized patients is typically assessed
by volume, most commonly using days of therapy per 1,000
patient days (DOT/1,000 PD).3 DOT, however, does not assign
value to the antimicrobial spectrum of drug exposure. For
example, a hospital whose patients receive 500 DOT/1,000 PD of
mostly narrow-spectrum antibiotics (eg, ampicillin for pneu-
monia) would appear the same as a hospital using 500 DOT/
1,000 PD dominated by broader-spectrum agents (eg, cefepime
for pneumonia). Similarly, a quality improvement initiative that
narrows the spectrum of coverage for perforated appendicitis
from meropenem to ceftriaxone plus metronidazole would
result in higher DOT/1,000 PD. Because volume of prescribing
and spectrum might not be highly correlated, a complementary
metric capable of assessing the antimicrobial spectrum of com-
posite antimicrobial use would provide an additional dimension
to the evaluation of ASP activities and their impact.
To address this gap, we developed an antibiotic spectrum
index (ASI) designed to measure and compare the relative
breadth of antibiotic spectrum used in hospitals.We then applied
this novel metric, in conjunction with DOT, to characterize and
compare antibiotic use across US children’s hospitals.
methods
Development of Antibiotic Spectrum Index
A group of 4 infectious diseases clinicians with expertise in
antimicrobial stewardship practice and research (J.S.G., A.L.H.,
M.P.K., J.G.N.) and 1 ASP clinical pharmacist (T.A.M.)
independently classiﬁed antibiotics, assigning each a point value
based on spectrum of activity against clinically relevant
pathogens (Table 1). Discrepancies between raters were
resolved through review of published data, pharmacy databases
(eg, Lexicomp), and iterative discussion until consensus was
achieved. One point was given for activity against each of the
following pathogens: methicillin-sensitive Staphylococcus aureus
(MSSA), methicillin-resistant S. aureus (MRSA), Enterococcus
faecalis, vancomycin-resistant Enterococcus faecalis (VRE),
Escherichia coli and Klebsiella, ampC producers, extended-
spectrum β-lactamase (ESBL) E. coli/Klebsiella, Pseudomonas
aeruginosa, penicillin-resistant pneumococcus (PRP),Moraxella
and Haemophilus inﬂuenzae, Mycoplasma and Chlamydophila,
anaerobes (1 point; 2 points for Bacteriodes fragilis). Multidrug-
resistant organism (MDRO)–active agents received an addi-
tional point, so the overall ASI for each agent could range from 0
to 14 points. For example, vancomycin received 1 point each for
MSSA, MRSA, E. faecalis, PRP, and MDRO (ASI= 5), whereas
oxacillin received 1 point only for MSSA (ASI= 1). To obtain an
aggregate ASI for a patient on a single day, the ASI of all
antibiotics prescribed were summed. Thus, a patient receiving
both vancomycin and piperacillin-tazobactam (ASI= 8) on the
same day results in a total daily ASI= 13.
Antibiotic Spectrum Index by Condition
To illustrate how the index can vary by condition and identify
conditions for potential stewardship intervention, we sum-
marized ASI by condition using all patient reﬁned-diagnosis
related groups (APR-DRG). Data were obtained from
the Pediatric Health Information System (PHIS), a database of
freestanding US children’s hospitals and included inpatient
and observation patients <18 years old, discharged in 2013
from 1 of 44 hospitals, who also received a systemic antibiotic.
We calculated the ASI per patient day among patients who
received any antibiotic.
Application to Community-Acquired Pneumonia (CAP)
Our goal was to develop a metric capable of measuring the
variability in antibiotic use across institutions as well as the
potential impact of interventions to improve antibiotic use.
Therefore, we applied the metric in 2 different ways, using
CAP as an example because it is the most common indication
for antibiotics in US children’s hospitals.4 Using the PHIS
database, we included children 6 months to 17 years old
treated with systemic antibiotics for CAP.5
First, we conducted a cross-sectional analysis of children
discharged in 2013 to illustrate how the ASI can be used to
characterize antibiotic use for pneumonia by hospital and to
compare the ASI per antibiotic day to DOT/1,000 PD.
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table 1 . Antibiotic Spectrum Index Matrix











Citrobacter ESBL Pseudomonas MRSA
Penicillin-
resistant
pneumonae VRE Atypical MDRO
Antibiotic Spectrum
Index
Dicloxacillin 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1
Oxacillin 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1
Amoxicillin 0 1 0 0 0 1 0 0 0 0 0 0 0 0 2
Ampicillin 0 1 0 0 0 1 0 0 0 0 0 0 0 0 2
Cephalexin 1 0 0 0 0 1 0 0 0 0 0 0 0 0 2
Erythromycin 0 0 0 0 1 0 0 0 0 0 0 0 1 0 2
Erythromycin 0 0 0 0 1 0 0 0 0 0 0 0 1 0 2
Metronidazole 0 0 1 1 0 0 0 0 0 0 0 0 0 0 2
Penicillin 0 1 1 0 0 0 0 0 0 0 0 0 0 0 2
Aztreonam 0 0 0 0 1 1 0 0 1 0 0 0 0 0 3
Cefazolin 1 0 0 0 1 1 0 0 0 0 0 0 0 0 3
Cefdinir 1 0 0 0 1 1 0 0 0 0 0 0 0 0 3
Ceﬁxime 0 0 1 0 1 1 0 0 0 0 0 0 0 0 3
Cefpodoxime 1 0 0 0 1 1 0 0 0 0 0 0 0 0 3
Rifampin 1 0 0 0 1 0 0 0 0 1 0 0 0 0 3
Azithromycin 1 0 1 0 1 0 0 0 0 0 0 0 1 0 4
Cefprozil 1 0 1 0 1 1 0 0 0 0 0 0 0 0 4
Ceftazidime 0 0 1 0 1 1 0 0 1 0 0 0 0 0 4
Cefuroxime 1 0 1 0 1 1 0 0 0 0 0 0 0 0 4
Chloramphenicol 0 0 1 1 1 1 0 0 0 0 0 0 0 0 4
Clarithromycin 1 0 1 0 1 0 0 0 0 0 0 0 1 0 4
Clindamycin 1 0 1 1 0 0 0 0 0 1 0 0 0 0 4
Piperacillin 0 1 1 0 0 1 0 0 1 0 0 0 0 0 4
Trimethoprim-
sulfamethoxazole
1 0 0 0 1 1 0 0 0 1 0 0 0 0 4
Cefotaxime 1 0 1 0 1 1 0 0 0 0 1 0 0 0 5
Cefoxitin 1 0 1 1 1 1 0 0 0 0 0 0 0 0 5
Ceftriaxone 1 0 1 0 1 1 0 0 0 0 1 0 0 0 5
Colistimethate 0 0 0 0 0 1 1 1 1 0 0 0 0 1 5
Daptomycin 1 1 0 0 0 0 0 0 0 1 0 1 0 1 5
Doxycycline 1 0 0 0 1 1 0 0 0 1 0 0 1 0 5
Gentamicin 1 0 0 0 1 1 0 0 1 1 0 0 0 0 5
Minocycline 1 0 0 0 1 1 0 0 0 1 0 0 1 0 5
Telavancin 1 1 0 0 0 0 0 0 0 1 1 0 0 1 5
Tobramycin 1 0 0 0 1 1 0 0 1 1 0 0 0 0 5
Vancomycin 1 1 0 0 0 0 0 0 0 1 1 0 0 1 5
Amikacin sulfate 1 0 0 0 1 1 0 0 1 1 0 0 0 1 6
Amoxicillin-clavulanate 1 1 1 1 1 1 0 0 0 0 0 0 0 0 6
Ampicillin-sulbactam 1 1 1 1 1 1 0 0 0 0 0 0 0 0 6
Cefepime 1 0 0 0 1 1 1 0 1 0 1 0 0 0 6
Linezolid 1 1 0 0 0 0 0 0 0 1 1 1 0 1 6
Ticarcillin-clavulanate 1 0 1 1 1 1 0 0 1 0 0 0 0 0 6
Ceftaroline 1 1 0 0 1 1 1 0 0 1 1 0 0 1 8
Ciproﬂoxacin 1 1 0 0 1 1 1 1 1 0 0 0 1 0 8
Piperacillin-tazobactam 1 1 1 1 1 1 1 0 1 0 0 0 0 0 8
Ertapenem 1 0 1 1 1 1 1 1 0 0 1 0 0 1 9
Levoﬂoxacin 1 1 1 0 1 1 1 1 0 0 1 0 1 0 9
Meropenem 1 0 1 1 1 1 1 1 1 0 1 0 0 1 10
Moxiﬂoxacin 1 1 1 1 1 1 1 0 0 1 1 0 1 0 10
Imipenem-cilastatin 1 1 1 1 1 1 1 1 1 0 1 0 0 1 11
Tigecycline 1 1 1 1 1 1 1 1 0 1 1 1 1 1 13
NOTE. MSSA, methicillin-sensitive staphylococcus aureus; ESBL, extended-spectrum β-lactam; MRSA, methicillin-resistant staphylococcus aureus; VRE, vancomycin-resistant
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To obtain estimates standardized by sex and age category
(ie, <5 years old, 5–11 years old, ≥12 years old), we ﬁt Poisson
models with offset of patient days or antibiotic days as
appropriate with hospitals included as ﬁxed effects.
Second, we conducted a longitudinal analysis to examine
how the ASI was impacted by a stewardship intervention
speciﬁcally designed to address overuse of broader-spectrum
antibiotics. We used a previously published intervention
designed to increase ampicillin prescribing instead of
broader-spectrum agents (eg, ceftriaxone) for CAP, imple-
mented by an ASP at a freestanding children’s hospital.6
Using a longitudinal piecewise Poisson model with a knot
at the intervention, we modeled the trajectory of prescri-
bing (DOT/1,000 PD and ASI per antibiotic day) before
and after the intervention, controlling for sex and age
category.7
ﬁgure 1. Comparison of days of therapy (DOT) and antibiotic spectrum index (ASI) of antibiotic use for treatment of community-acquired
pneumonia (CAP). Panel A: Comparison across 44 hospitals. Each dot is a hospital. Dashed lines represent median hospital value. An antibiotic
day is a patient day with a systemic antibiotic. Panel B: Impact of an antimicrobial stewardship intervention on antibiotic treatment at a single
hospital. On the left y-axis, black line and black dots represent the ﬁtted and raw values, respectively, ASI per antibiotic day. On the right y-axis,
dashed line and white diamonds represent the ﬁtted and raw values, respectively, DOT per 1,000 PD. Abbreviation: PD, patient days.
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results
Antibiotic Spectrum Index by Condition
In 2013, 352,396 children received systemic antibiotics on
1,626,071 patient days (antibiotic days). The mean ASI per
antibiotic day was 5.7 (standard deviation, 3.0). Among con-
ditions previously identiﬁed with high antibiotic DOT,4 the
mean ASI per antibiotic day distinguished conditions by type
of use (narrow: 5.6 SSTI, 6.3 pneumonia; medium: 7.9
appendectomy; broad: 10.3 bone marrow transplant, 13.8
cystic ﬁbrosis).
Application to Community-Acquired Pneumonia
We identiﬁed 9,602 children with CAP discharged in 2013.
Plotting ASI per antibiotic day with DOT/1,000 patient days
revealed an added dimension of the variability in antibiotic use
across hospitals (Figure 1A). Here, DOT/1,000 PD and ASI
were poorly correlated (r= 0.16). Examining the impact of an
ASP intervention targeting children with CAP revealed no
change in the DOT/1,000 PD, but a change in ASI per
antibiotic day was observed (Figure 1B).
discussion
We classiﬁed systemic antibiotics using an index based on
spectrum of activity against clinically relevant pathogens. The
ASI revealed variability in antibiotic use across hospitals and
was sensitive to changes in antibiotic selection in ways not
detectable using the standard ASP metric, DOT/1,000 PD. The
ASI highlights a new opportunity to benchmark antibiotic use
and to assess the impact of ASP interventions alongside the
more commonly used DOT/1,000 PD.
The ASI addressed elements of the more complex algorithm
developed by Madras-Kelly et al,8 the pragmatic 5-category
approach taken by Stenehjem et al,9 and the antibiotic
groupings in the CDC AUR module10 to generate a novel
scoring system that is simple, objective, and discriminatory.
When plotted alongside DOT, ASI revealed an added dimen-
sion of variability in composite antibiotic use across hospitals.
When applied to a speciﬁc inpatient ASP intervention
(narrowing therapy for CAP),6 the ASI revealed a change in
prescribing behavior not evident using DOT. Similarly, in the
previously described change of appendicitis therapy from
meropenem to ceftriaxone/metronidazole, the DOT doubled
while the ASI dropped from 10 to 7. Thus, the ASI can be
applied to a speciﬁc diagnosis, patient population, or an entire
center to assess antibiotic use.
The ASI has limitations. This approach scores coverage of
different pathogens similarly (eg, mycoplasma andMRSA each
receive 1 point) and dichotomously (“yes” or “no” instead of
speciﬁc proportion). Furthermore, the ASI has not been
validated to reﬂect adverse clinical outcomes that drive the
preference for using narrower-spectrum agents, including
antibiotic resistance, Clostridium difﬁcile infection, and
disruption of the host microbiome. Lastly, the analysis
focused on antibiotic prescribing in children’s hospitals;
however, this metric can be applied broadly to all settings and
populations.
In conclusion, the application of an antibiotic spectrum
index generates expected patterns based on antibiotic choices
across conditions, facilitates interhospital benchmarking and
comparisons, and can be used in conjunction with DOT/1,000
PD to identify important clinical targets for antimicrobial
stewardship.
acknowledgments
Financial support: No ﬁnancial support was provided relevant to this article.
Potential conﬂicts of interest: All authors report no conﬂicts of interest
relevant to this article.
Afﬁliations: 1. Division of Infectious Diseases and The Center for Pediatric
Clinical Effectiveness, Children’s Hospital of Philadelphia, Philadelphia,
Pennsylvania; 2. Perelman School of Medicine at the University of Pennsyl-
vania, Philadelphia, Pennsylvania; 3. Division of Pediatric Infectious Dis-
eases, Department of Pediatrics, University of Utah, Salt Lake City, Utah;
4. Division of Infectious Diseases, Seattle Children’s Hospital, Seattle,
Washington; 5. Division of Pediatric Infectious Diseases, Washington Uni-
versity, St. Louis, Missouri; 6. Antimicrobial Stewardship Program, Ofﬁce of
Safety and Medical Operations, Children’s Hospital of Philadelphia, Philadel-
phia, Pennsylvania.
Address correspondence to Jeffrey S. Gerber, MD, PhD, Division of Infec-
tious Diseases, The Children’s Hospital of Philadelphia, CHOP North, Suite
1518, Philadelphia, PA 19104 (gerberj@email.chop.edu).
PREVIOUS PRESENTATION: The work reported here was presented at ID
Week 2014 on October 10, 2014, in Philadelphia, Pennsylvania.
Received February 17, 2017; accepted April 13, 2017; electronically
published May 31, 2017
© 2017 by The Society for Healthcare Epidemiology of America. All rights
reserved. 0899-823X/2017/3808-0016. DOI: 10.1017/ice.2017.94
references
1. Policy statement on antimicrobial stewardship by the Society for
Healthcare Epidemiology of America (SHEA), the Infectious
Diseases Society of America (IDSA), and the Pediatric Infectious
Diseases Society (PIDS). Infect Control Hosp Epidemiol
2012;33:322–327.
2. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an
antibiotic stewardship program: guidelines by the Infectious
Diseases Society of America and the Society for Healthcare
Epidemiology of America. Clin Infect Dis 2016;62:e51–e77.
3. Moehring RW, Anderson DJ, Cochran RL, Hicks LA, Srinivasan A,
Dodds Ashley ES. Expert consensus onmetrics to assess the impact
of patient-level antimicrobial stewardship interventions in acute-
care settings. Clin Infect Dis 2017;64:377–383.
4. Gerber JS, Kronman MP, Ross RK, et al. Identifying targets for
antimicrobial stewardship in children’s hospitals. Infect Control
Hosp Epidemiol 2013;34:1252–1258.
5. Ross RK, Hersh AL, Kronman MP, et al. Impact of Infectious
Diseases Society of America/Pediatric Infectious Diseases Society
996 infection control & hospital epidemiology august 2017, vol. 38, no. 8
https://www.cambridge.org/core/terms. https://doi.org/10.1017/ice.2017.94
Downloaded from https://www.cambridge.org/core. Washington University School of Medicine - St Louis, on 27 Aug 2017 at 20:50:37, subject to the Cambridge Core terms of use, available at
guidelines on treatment of community-acquired pneumonia in
hospitalized children. Clin Infect Dis 2014;58:834–838.
6. Newman RE, Hedican EB, Herigon JC, Williams DD, Williams
AR, Newland JG. Impact of a guideline on management of
children hospitalized with community-acquired pneumonia.
Pediatrics 2012;129:e597–e604.
7. Fitzmaurice GM, Laird NM. Applied Longitudinal Analysis. 2nd
ed. Hoboken, NJ: Wiley & Sons; 2011.
8. Madaras-Kelly K, Jones M, Remington R, Hill N, Huttner B,
Samore M. Development of an antibiotic spectrum score
based on veterans affairs culture and susceptibility data for
the purpose of measuring antibiotic de-escalation: a modiﬁed
Delphi approach. Infect Control Hosp Epidemiol 2014;35:
1103–1113.
9. Stenehjem E, Hersh AL, Sheng X, et al. Antibiotic use in small
community hospitals. Clin Infect Dis 2016;63:1273–1280.
10. Antimicrobial use and resistance (AUR) module. Centers for
Disease Control and Prevention website. https://www.cdc.gov/
nhsn/PDFs/pscManual/11pscAURcurrent.pdf. Published 2017.
Accessed April 1, 2017.
antibiotic spectrum index 997
https://www.cambridge.org/core/terms. https://doi.org/10.1017/ice.2017.94
Downloaded from https://www.cambridge.org/core. Washington University School of Medicine - St Louis, on 27 Aug 2017 at 20:50:37, subject to the Cambridge Core terms of use, available at
